# Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma

> **NCT07741643** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 30 (estimated)

## Conditions studied

- HNSCC,Larynx, Pharynx and Oral Cavity
- Squamous Cell Carcinoma
- Head and Neck Cancer
- Head and Neck Surgery

## Interventions

- **DRUG:** Panitumumab-IRDye800
- **DRUG:** [18F]NOTA-ABY-030

## Key facts

- **NCT ID:** NCT07741643
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2031-07
- **Final completion:** 2031-07
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07741643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07741643, "Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07741643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*